Genekon Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -644.01%
- Ebitda -637.60%
- Net Worth -112.31%
- Total Assets -97.77%
About Genekon Pharmaceutical
Genekon Pharmaceutical Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 June 2015 (Nine years and seven months 15 days old ). Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chetan Chopda, Pramod Chede, and Datta Dhawade serve as directors at the Company.
Company Details
-
Location
Nagpur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100MH2015PTC265790
-
Company No.
265790
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Jun 2015
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Genekon Pharmaceutical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chetan Chopda
|
Director | 20-Jun-2015 | Current |
|
Pramod Chede
|
Additional Director | 09-Nov-2020 | Current |
|
Datta Dhawade
|
Director | 24-Nov-2022 | Current |
Financial Performance of Genekon Pharmaceutical.
Genekon Pharmaceutical Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 644.01% decrease in profit. The company's net worth observed a substantial decline by a decrease of 112.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genekon Pharmaceutical?
In 2018, Genekon Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Being Innovation Private LimitedPramod Chede is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genekon Pharmaceutical?
Unlock and access historical data on people associated with Genekon Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genekon Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genekon Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
